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Gastrointestinal stromal tumors (GISTs) are composed of various molecular subtypes, with 
differing prognostic and predictive relevance. Previously, tumors lacking mutations in the 
KIT and PDGFRA genes have been designated as ‘wild-type’ GISTs; however, they represent a 
heterogeneous group currently undergoing further subclassification. Primary and secondary 
resistance to imatinib poses a significant clinical challenge, therefore ongoing research is 
trying to evaluate mechanisms to overcome resistance. Thorough understanding of the 
prognostic and predictive relevance of different genetic subtypes of GIST can guide clinical 
decision-making both in the adjuvant and the metastatic setting. Further work is required 
to identify tailored therapies for specific subgroups of GISTs wild-type for KIT and PDGFRA 
mutations and to identify predictive factors of resistance to currently approved systemic 
therapies.
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Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the diges-
tive tract, representing 0.1–3% of all GI cancers. GISTs can arise from any part of the GI tract, 
primarily within the muscular wall of the stomach and small intestine and rarely in extra-intestinal 
locations (omentum, mesentery, retroperitoneum or pelvic cavity) [1]. The cells of origin of GISTs 
are thought to be the interstitial cells of Cajal or their precursors [2]. GISTs represent a wide spec-
trum of disease, with aggressiveness of the disease correlating with tumor size, mitotic activity 
and anatomical origin (these three clinicopathological features forming the basis of currently used 
risk-stratification systems) [1,3–5].
Surgery is the mainstay of management for localized GIST and is curative in 45–60% of cases [3,4]. 
Locally advanced or metastatic GISTs are notoriously refractory to conventional chemotherapy or 
radiation. The discovery of the KIT tyrosine kinase receptor and subsequently that of the mutually 
exclusive KIT and PDGFRA gain of function mutations have provided a paradigm shift in the way 
we classify, diagnose and most importantly treat GISTs. Studies of KIT/PDGRA mutation negative 
or ‘wild-type’ (WT) GISTs have uncovered numerous other molecular groups, including mutations in 
BRAF and subunits of the succinate dehydrogenase (SDH) complex. Routine genotyping has become 
an integral part of management of GISTs undergoing tyrosine kinase inhibitor (TKI) therapy [5].
The objective of this manuscript is to mirror the evolution of GIST subclassification based 
on genetic profiling and to highlight the distinct prognostic and predictive relevance of already 
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well-characterized and yet emerging genetic 
alterations in GIST. We separate in our discus-
sion the prognostic and predictive relevance 
of specific genetic subtypes of GIST, therefore 
providing a more transparent guide for clini-
cal decision-making in both the adjuvant and 
 metastatic setting.
The KiT receptor tyrosine kinase
The c-kit proto-oncogene is allelic with the 
murine white-spotting locus (W), mutations 
of which affect melanogenesis, gametogenesis 
and hematopoiesis during development and in 
adult life [6]. c-kit encodes the 145-kDA receptor 
tyrosine kinase (RTK) KIT and is the normal 
cellular homolog of the viral oncogene v-kit, the 
transforming gene of the Hardy–Zuckermann 
4 feline sarcoma virus [7]. KIT is a member of 
the type III RTK family which includes the 
PDGFRA and PDGFRB, the macrophage col-
ony-stimulating-factor receptor (CSF1R) and 
the Fl cytokine receptor (FLT3) [8]. The CD117 
antibody against KIT has previously been shown 
to be a sensitive and specific marker for GIST, 
being positive in 95% of GIST specimens [9].
The KIT transmembrane receptor is com-
posed of an extracellular domain consisting of 
five immunoglobulin (Ig) like motifs, a trans-
membrane hinge, a juxta-membrane (JM) 
domain and an intracellular tyrosine kinase 
domain consisting of two regions separated by 
a kinase insert domain (KID). The different 
segments of the KIT receptor all have a specific 
designated role in the process of tyrosine kinase 
activation (Table 1).
In around 82–87% of all cases, GISTs have 
activating mutations in either the KIT or the 
homologous PDGFRA RTKs (Table 2). Gain of 
function mutation of either KIT or PDGRA 
receptors lead to constitutive, ligand-independ-
ent activation that results in the activation of 
Ras/Raf/MAPK, JAK/STAT3 and PI3K/
Akt/mTOR downstream pathways, ultimately 
increasing cell proliferation and inhibiting 
apoptosis [10,17].
●● KIT exon 9, 11, 13, 17 mutant GiST
While most KIT mutations in GIST are somatic, 
germline mutations have been identified in a 
small number of families [5]. Gain-of-function 
mutations in KIT result in growth advantage 
by constitutive, ligand-independent activation 
of the RTK [18]. While most GISTs are hete-
rozygous for a given mutation, in around 15% 
of tumors the remaining WT KIT allele is lost 
and this is associated with malignant behavior, 
increased mitotic activity and topoisomerase II 
expression [19].
Approximately 69–83% of all GISTs show 
a KIT mutation (Table 2). An important obser-
vation is that KIT detection by immunohisto-
chemistry (IHC) is unrelated to the existence 
of underlying mutations. The vast majority of 
KIT ’ ‘hot spot’ mutations are found in exon 11, 
less frequently in exon 9 and rarely in exon 13 
and exon 17 (Table 2) [20]. Primary nonhot spot 
exon 8 mutation of the KIT receptor is extremely 
rare and is not routinely screened for (Table 2) [11].
●● KIT exon 11 mutational landscape
The most common site of KIT mutation is in the 
5′ end of exon 11, which encodes the JM domain, 
and in the overwhelming majority of cases dele-
tions or substitutions involving codons 550–560 
occur [12]. Genetic alterations in exon 11 dis-
rupt the auto-inhibitory function and  trigger 
ligand-independent receptor activation [21].
There is a constantly growing body of evi-
dence that the exact types of genetic alterations 
hold strong clinical prognostic value of their 
own [13,14]. Wozniak and colleagues analyzed 
clinical follow-up data of 427 patients who 
Table 1. KiT receptor function and primary mutational status in gastrointestinal stromal tumors.
Coding 
region
KiT 
segment
Physiological function Primary 
mutation rate
Ref.
Exon 8 EC IGM SCF/ligand binding; dimerization domain 0.15–0.23% [10,11]
Exon 9 EC IGM SCF/ligand binding triggering subsequent receptor homodimerization, conformational 
change and kinase activation
7–15% [10,12–13]
Exon 11 JM Auto-inhibition of the receptor in ligand-free state 61–71% [10,12,14]
Exon 13 PKD ATP-binding region 0.5–1.8% [10,12,14]
Exon 14 KID Undefined function beyond linking PKD with the DKD NDA [10]
Exon 17 DKD Contains the activation loop that stabilizes the activated receptor 0.5–1% [10,12,15]
NDA: No data available as primary mutation [10–16]. 
DKD: Distant kinase domain; EC IGM: Extracellular immunoglobulin-like motif; JM: Juxta-membrane domain; PKD: Proximal kinase domain; SCF: Stem cell factor.
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underwent curative resection for GIST in Poland 
between 1999 and 2009. Surgical specimens of 
imatinib-naive GISTs from this period were 
prospectively included in the Polish Clinical 
GIST Registry. Mutational analysis was retro-
spectively carried out assessing for exon 9, 11, 
13, 17 KIT and exon 12, 14, 18 PDGFRA muta-
tional status [14]. The European ConticaGIST 
database study analyzed the clinicopathologic 
and molecular data (exon 9, 11, 13, 17 KIT 
and exon 12, 14, 18 PDGFRA) of 1,056 GIST 
patients undergoing curative R0/R1 resection. 
Patients were diagnosed between January 1985 
and April 2012 with 13 contributing institutions 
from four European countries. As a strength of 
the ConticaGIST series, the majority of the cases 
(all those diagnosed from 2001) were studied 
prospectively (83% of all) [13]. None of the 
patients in either studies were exposed to chemo-
therapy or any other anticancer agent, including 
imatinib, thus both studies provide invaluable 
prognostic information on the clinical course 
of GIST according to specific tumor genotype.
exon 11 deletions
Deletions affecting codons 557–558 of exon 11 of 
the c-KIT gene are detected in 23.2–27.7% of all 
GIST cases. They are lost either as specific isolated 
p.W557_K558 deletions in 6.3–7.5% of GISTs or 
as part of larger deletions in 15.7–21.4% of the 
cases (Table 3). Early studies associated deletions 
affecting codons 557–558 with an aggressive, 
metastasizing phenotype and indicate an overall 
poor prognosis [22,23] Interestingly Martin-Broto 
and colleagues demonstrated that the predic-
tive value of deletion of 557/558 for recurrence 
might be limited only to the first 4 years after 
curative surgery [24]. In the Polish registry study 
557/558 codon deletions were more frequent in 
larger (88%, >5 cm) GISTs with higher mitotic 
index (MI; 75% with >5/50 HPF) and thus 80% 
of them stratified as high-risk tumors. Patients 
with 557/558 codon deletions had a lower 
23.8% 5-year relapse-free survival (RFS) rate as 
compared with patients with any other KIT exon 
11 mutations (41.8% RFS), but also with other 
exon 11 deletions that have not involved codons 
557/558 (33.3% RFS) [14].
In the Multinational European ConticaGIST 
Database analysis KIT p.W557_K558del mutants 
equally segregated in gastric and nongastric sites 
(55 vs 45%). KIT p.W557_K558del was more 
frequently identified in patients younger than 
60 years of age (59 vs 42.4%), in tumors’ >5 cm 
(84.5 vs 57.7%), with MI >5/50 HPF (68.9 
vs 39.4%), and classified as high risk (70.2 vs 
38.9%), when compared with other KIT exon 
11 mutated tumors. It was an important obser-
vation that the clinicopathologic characteristics 
of tumors bearing KIT p.W557_K558del were 
comparable with the group of tumors with KIT 
delinc557/558, within which tumor size, mitotic 
rate and fraction of high-risk tumors were also 
significantly higher than in tumors with other 
KIT exon 11 mutants. KIT delinc557/558 was 
associated with an increased risk for tumor pro-
gression with a hazard ratio (HR) of 1.45 and an 
inferior disease-free survival (DFS; median DFS 
45.5 months; 5-year DFS 33.1%). The relatively 
high number of KIT del-inc557/558 mutants 
equally distributed in gastric and nongastric 
sites enabled the researchers to analyze the pos-
sible impact of this genotype on DFS, depend-
ing on the anatomical site of GISTs. In clear 
contrast with other KIT exon 11, KIT exon 9 
and PDGFRA exon 18 mutations, the poor prog-
nostic impact of KIT del-inc557/558 on patients’ 
survival was only significant in GIST localized 
to the stomach (p < 0.001), but not in tumors’ 
with nongastric origin (p < 0.26). The same asso-
ciations were also evident when comparing KIT 
del-inc557/558 mutants with other exon11 KIT 
mutations, overall (p < 0.0001; or comparing 
gastric (p < 0.0001) and nongastric (p < 0.599) 
GIST. This phenomenon might be related to 
the observation that gastric GIST with KIT 
del-inc557/558 had a larger size (7 vs 5.8 cm) 
and a higher mitotic rate (6 vs 4/50 HPF) when 
Table 2. KIT and PDGFRA ‘hot spot’ mutation landscape.
Study (type) OMR 
(%) 
KIT (exon); % PDGFRA (exon); % Ref.
  All  9  11  13  17  All  18  18*  14  12   
Polish (registry) 82.2 69.3 7.3 61.1 0.5 0.5 12.9 11.9 8.2 0.7 0.2 [12]
ConticaGIST (registry) 85.1 71.1 7.4 71.1 1.8 0.6 14 12.8 9.8 0.3 0.9 [14]
EORTC 62005 (Phase III trial) 86.2 83.6 15.4 65.8 1.6 0.8 1.6 NS 1 NS NS [13]
CALGB 150105 (Phase III trial) 84.6 81.9 8.2 71.3 1.2 1.0 2.65 1.2 0.9 NS 0.23 [15]
ACOSOG Z9001 (Phase III trial) 87.4 76.2 6.9 67.3 1.8 0.2 11.2 NS 5.3 NS NS [16]
18*: PDGFRA exon 18 pD842V mutation; NS: Not specified; OMR: Overall mutation rate.
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compared with other KIT exon 11 mutants. 
Consequently, the fraction of patients with 
gastric GIST harboring KIT del-inc557/558 
who relapsed 5 years after surgery was twice as 
high as patients with other KIT exon 11 muta-
tions (61 vs 29%). Even in tumors classified as 
nonhigh risk ([very]low and intermediate) and 
originating from the stomach, the presence of 
KIT del-inc557/558 remained an important 
prognosticator for poor outcome in comparison 
with other KIT exon 11 mutations, KIT exon 9 
and PDGFRA exon 18 mutations [13].
intron 10/exon 11 junction deletions
In the Polish registry series six GISTs (1.4% of 
all) had deletions affecting the intron 10/exon 
11 junction, resulting in p.K550_K558 deletion 
as such. Among these handful GISTs all but one 
tumor was high risk or overtly malignant at pres-
entation, suggesting a more aggressive clinical 
behavior of tumors with such deletion [14].
KIT exon 11 single nucleotide substitutions
A discrepancy in the frequency of KIT exon 11 
substitutions between population-based studies 
15.5–28.6% and tumor material from clinical 
trials 1.6–1.86% has been observed (Table 3). 
The under-representation of KIT exon 11 sub-
stituted GISTs in the advanced/metastatic 
GIST trials would suggest a more indolent clini-
cal behavior. In a Norwegian population study, 
the presence of point mutations was associated 
with a low mitotic count [25]. In the Polish regis-
try study tumors with KIT exon 11 substitutions 
were also characterized by low mitotic activ-
ity and average size <5 cm. Patients with KIT 
substitutions have also been shown to have a 
better 5-year RFS rate (50.7%) than those with 
KIT deletions or duplications (28.1 and 40.0%, 
respectively) [14].
Duplications in KIT exon 11
Duplications in KIT exon 11 were historically 
associated with gastric tumor location and 
female gender, and also linked with a favora-
ble clinical course [26]. The results of the Polish 
registry study confirmed this association since 
26 out of 30 GISTs with 3′-end internal tan-
dem duplications were of gastric origin and 
21 of them were found in women. A relatively 
Table 3. exon 11 mutations and their prognostic implications.
Genetic alteration Study/mutation frequency Clinical–pathological prognostic features Ref.
p.W557_K558 deletion 
 
 
 
 
Polish Registry 7.5% 
ConticaGIST 6.3% 
Norwegian Registry 5.3% 
EORTC 62005 6.9% 
High-risk tumors 
Higher MI, larger (>5 cm) size 
Gastric: nongastric location 1:1 
Younger age at presentation (<60 years) 
Lower RFS rate compared with all other (KIT exon 9 and PDGFRA exon 18) 
and to other exon 11 mutations 
Prognostic power seems to be confined to gastric location of GISTs
[12–15,25]
KITdelinc557/558 Polish Registry 15.7% 
ConticaGIST 21.4%
High-risk tumors 
Higher MI, larger (>5 cm) size 
Gastric: nongastric location 1:1 
Younger age at presentation (<60 years) 
Lower RFS rate compared with all other (KIT exon 9 and PDGFRA exon 18) 
and to other exon 11 mutations 
Prognostic power seems to be confined to gastric location of GISTs
[12–15,25]
Intron 10/exon 11 junction 
deletions (resulting in 
p.K550_K558 deletion)
Polish Registry 1.4% High-risk tumors 
Presumed aggressive/metastasizing clinical behavior
[14]
Single nucleotide 
substitutions
Polish Registry 15.5% 
ConticaGIST 19.7% 
CALGB 150105 1.6% 
EORTC 62005 1.8%
Lower MI, smaller (<5 cm) size 
Indolent clinical course 
Better 5-year RFS (as compared with KIT deletions or duplications)
[12–15]
Duplications Polish Registry 7% 
ConticaGIST 6.6% 
EORTC 62005 1.5%
Exclusive gastric location 
Benign clinical outcome
[12–14]
Homo/hemizygous KIT 
exon 11 mutant
Polish Registry 4% High risk of early metastatic disease 
Disseminated malignancy at presentation
[14]
GIST: Gastrointestinal stromal tumor; MI: Mitotic index; RFS: Relapse-free survival.
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good clinical outcome has also been observed in 
patients with these tumors [14].
Homo/hemizygous KIT exon 11 mutation 
status
Loss of the WT KIT 11 allele and presence 
of homozygous KIT exon 11 mutations was 
strongly associated with a malignant clinical 
behavior in gastrointestinal stromal tumors [27]. 
In the Polish registry study 4% (17) of KIT exon 
11 mutant GISTs lacked a WT allele [14], indi-
cating a homo/hemizygous KIT status. Eleven 
of the 17 cases were associated with a high risk 
of metastatic disease or were already dissemi-
nated at the time of presentation, corroborating 
p revious findings.
exon 9 KIT A502_Y503 duplication
KIT mutations in exon 9 coding for the extra-
cellular domain occur in 7–15% of GIST cases 
(Table 2). These mutations are believed to mimic 
the conformational change that the extracel-
lular KIT receptor undergoes when ligand is 
bound. KIT exon 9 mutations characterized by 
A502-Y503 codon duplications are almost exclu-
sively found in intestinal GISTs and for long 
they have been associated with a more aggressive 
phenotype [28].
In the Polish registry study KIT A502_
Y503dup mutation was not only associated with 
a small intestinal origin (27 out of 31 tumors) 
and malignant behavior, but also with a male 
predominance (21 out of 31) [14].
In contrast to previous observations 
Künstlinger and colleagues in 2013, described 
for the first time that nearly 20% of KIT 
exon 9-mutated GISTs actually occur in the 
stomach or rectum. They provided evidence that 
exon 9-mutated GISTs metastasize significantly 
more often to the peritoneum than to the liver. 
Analyzing the data of over 1500 GISTs from 
their registry, KIT exon 9 mutations were neither 
associated with intermediate-risk/high-risk sta-
tus nor overrepresented among metastatic lesions 
and thus they concluded that exon 9 mutations 
per se do not have a prognostic relevance [29].
In the ConticaGIST registry study when 
compared with KIT p.W557_K558del, KIT 
p.A502_Y503dup had a lower median mitotic 
rate, whereas there was no difference in tumor 
size for these mutants. Overall, both KIT exon 9 
and KIT del-inc557/558 mutants were associated 
with relatively equal and inferior DFS (median 
DFS in both groups, 45.5 months; 5-year DFS, 
37.9 and 33.1%, respectively). There is solid evi-
dence that compared with gastric tumors’, small 
intestinal tumors with similar size and mitotic 
activity have a markedly worse prognosis. 
Across the board GISTs localized outside of the 
stomach were larger, had a higher mitotic rate 
and had worse 5-year DFS (34.2 vs 58.1%) in 
comparison with gastric tumors. As mentioned 
above, comparison between tumors with KIT 
exon 9 and KIT exon 11 mutations (both, KIT 
del-inc557/558 and other KIT exon 11) of non-
gastric origin did not show differences in tumor 
clinical behavior as assessed by survival analysis. 
Thus, the authors concluded that in extra-gastric 
sites, the worse prognosis of KIT exon 9 mutants 
is related to the tumor location itself rather than 
to an intrinsic aggressive biologic nature of this 
mutation. In further support for this hypothesis, 
six out of seven gastric KIT exon 9 mutants in 
the ConticaGIST series study were classified as 
nonhigh risk, with only one of these patients 
developing progressive disease (PD), following 
a relatively long DFS of 56 months [13].
exon 13 & 17
It has been estimated that the frequency of 
exon 13 and 17 mutations is not higher than 
1–2% [30]. In the Polish registry study KIT 
tyrosine kinase domain mutations involving 
exons 13 and 17 were found in two cases each, 
supporting the notion that these are uncommon 
mutations [14]. Mutations in exon 17 encoding 
the activation loop of the kinase seem to stabi-
lize the active conformation. Primary mutations, 
such as that of K642E in exon 13 encoding the 
ATP-binding region are extremely rare and are 
speculated to interfere with the physiological 
auto-inhibitory function of the JM domain [30].
In a multicenter study of 54 cases with primary 
KIT exon 13 or exon 17 mutant GISTs, specifi-
cally among the KIT exon 17 mutants twice as 
many tumors arouse from the small bowel than 
the stomach. Intestinal site of origin of tumors 
was also over-represented among the KIT exon 
13 mutants as compared with population-based 
studies. Overwhelming majority of the KIT exon 
13 or exon 17 mutants displayed pure spindle-
cell morphology, very rarely associated with epi-
thelioid features. Gastric KIT exon 13 mutant 
GISTs were slightly larger and of a higher risk 
group than gastric GISTs on average, whereas 
the behavior of small intestinal GISTs with KIT 
exon 13 or KIT exon 17 mutations did not differ 
from other small intestinal GISTs [30].
10.2217/fon-2016-0192
review Szucs, Thway, Fisher et al.
future science group
●● PDGFRA mutant GiST
PDGFRA mutations are reported in 1.6–2.7% 
of GISTs in Phase III clinical trials enroll-
ing patients with advanced disease and up to 
12.9–14% of primary tumors in population 
studies (Table 2). The markedly lower represen-
tation of PDGFRA-mutated GISTs in clini-
cal trial material can be easily explained by a 
comparatively benign clinical behavior of these 
tumors. Historically they were indeed corre-
lated with a more indolent course of disease [31]. 
Moreover, PDGFRA mutant GISTs are almost 
exclusively (90–93%) of prognostically more 
favorable gastric origin. The most prevalent 
genotype is the p.D842V substitution involving 
the second kinase domain (which corresponds 
to exon 17 of KIT), detected in 60–65% of all 
PDGFRA mutated tumors (Table 2). PDGFRA 
and KIT mutations are mutually exclusive and 
activate similar downstream signal transduction 
pathways [32].
In the Polish registry study, most changes 
among PDGFRA mutated tumors were identi-
fied in exon 18 (11.9%), including the p.D842V 
substitution and with in-frame deletion or dele-
tion/insertion of different lengths (9–15 bp) in 
8.2 and 3.7% of the cases, respectively. Three 
cases (0.7%) showed substitution in exon 14 of 
PDGFRA (p.N659K), and one (0.2%) revealed 
deletion in exon 12 JM domain (p.S566_
E571delinsR). Multivariate analysis in this 
study revealed that patients with tumors with 
mutations involving PDGFRA, and KIT exon 11 
substitutions or duplications have lower risk of 
5-year relapse when compared with patients with 
KIT deletions involving codons 557/558 [14].
In the ConticaGIST series among tumors 
with PDGFRA mutations, the most prevalent 
was the p.D842V substitution (9.8% of all 
mutations and 65.2% of the PDGFRA exon 18 
mutations). PDGFRA exon 18 mutation status 
correlated with an extremely favorable disease 
outcome (median DFS not reached; 5-year DFS, 
75%) in comparison with other mutations. KIT 
exon 9 and KIT delinc557/558 mutations were 
associated with a significantly increased risk 
for tumor progression (HR: 1.47 and 1.45), 
in contrast with PDGFRA exon 18 mutation 
(HR: 0.23). There was no significant differ-
ence in DFS of PDGFRA p.D842V versus other 
PDGFRA exon 18 mutations. Notably, among 
gastric PDGFRA mutations, the vast major-
ity that progressed (11 of 14) carried an exon 
18 PDGFRA D842V substitution. While the 
number of the tumors with PDGFRA exon 18 
mutations originating from nontypical anatomi-
cal sites was too low for a conclusive analysis, the 
frequency of relapse was lower in gastric versus 
nongastric PDGFRA exon 18 mutated tumors 
(11.8 vs 25%), respectively [13].
It has been suggested that GISTs with the 
PDGFRA exon 14 mutation represent a subset 
of clinically favorable gastric tumors (exclusively 
gastric location) with almost exclusively epithe-
lioid morphology [33].
●● KIT/PDGFRA mutation-negative ‘wT’ GiST
Approximately 15% of adult GISTs do not have 
detectable mutations in KIT or PDGFRA and 
historically were simply referred to as ‘WT’ 
GISTs. KIT/PDGFRA WT GISTs express high 
levels of KIT and can arise from any part of the 
GI tract. Phosphorylated KIT is detectable in 
some of these tumors, suggesting KIT activation 
may still have a role in their pathophysiology [34].
●● SDH-deficient ‘wT’ GiST
About half of all KIT/PDGFRA WT GISTs have 
inactivating mutations in the genes coding one 
of the four (SDHA, SDHB, SDHC and SDHD) 
subunits of the SDH complex. The SDH com-
plex is located in the inner mitochondrial mem-
brane and plays a role in the electron transport 
chain and the Szent–Györgyi–Krebs cycle by 
replacing succinate to fumarate. Either gene 
mutations in any member of the SDH complex 
or an as-yet-unknown mechanism destabilizes 
the SDH complex. SDH enzyme dysfunction 
leads to accumulation of succinate, resulting in 
HIF1-α stabilization and HIF1-α controlled 
oncogene transcription. In WT GISTs without 
SDH activity, upregulation of HIF1-α may lead 
to increased growth signaling through IGF1R 
and VEGFR [35].
Double hit inactivation of any components 
of the SDH complex destabilizes the entire 
complex, resulting in degradation of the SDHB 
subunit. Several international groups have dem-
onstrated that all SDH mutations are reliably 
detected by SDHB loss on IHC, therefore, 
SDHB-IHC is currently the method of choice 
to test for SDH deficiency in KIT/PDGFRA WT 
GIST [35–37].
SDH gene germline mutations are features of 
the Carney–Stratakis syndrome, an inherited 
predisposition to multiple gastric GISTs and 
paragangliomas. Carney-triad is characterized 
by multiple gastric GISTs, paragangliomas and 
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pulmonary chondromas with no SDH gene ger-
mline mutations detected (despite a deficiency 
of SDHB immunoreactivity) [38]. However, 
most recently it was suggested that in rare occa-
sions the Carney triad can be allelic to Carney–
Stratakis syndrome. In the largest published 
cohort of 63 unrelated Carney triad patients six 
patients (9.5%) were found to have germline var-
iants in the SDHA, SDHB or SDHC genes [39]. 
Detecting SDH deficiency therefore, will trigger 
further clinical investigations in order to exclude 
syndromic GISTs, especially in younger patients.
SDH-deficient GISTs are particularly com-
mon in childhood and young adulthood, approx-
imately 1–2% of all GISTs occurring in the 
pediatric population [40]. These SDH-deficient 
pediatric GISTs are characterized by unique clin-
ical, morphological and genetic features. They 
have a predilection for the stomach, commonly 
demonstrate a multilobulated/multinodular 
growth pattern, frequently metastasize to 
lymph nodes and are mostly WT for KIT and 
PDGFRA [35,36].
Importantly SDH-deficient ‘pediatric-type’ 
GISTs also account for between 5 and 7.5% of all 
gastric GISTs occurring in adults [35]. It must be 
emphasized that the prognosis of SDH-deficient 
GISTs cannot be predicted by size and mitotic 
rate as even small, mitotically inactive SDH-
deficient GISTs may metastasize. Interestingly 
when metastases do occur they may be strikingly 
indolent, sometimes remaining stable for years 
or decades [37]. As their distinctive histology 
predicts genotype and clinical behavior it can 
be recommended that IHC for SDHB should 
be performed on gastric GISTs with compatible 
‘pediatric-type’ morphology.
In a recently published study SDHA muta-
tions were associated with statistically signifi-
cant better clinical outcome as compared with 
KIT/PDGFRA mutations and KIT/PDGFRA 
WT without SDH deficiency. All survival analy-
ses (from diagnosis of primary tumors and from 
diagnosis of metastatic disease) confirmed a far 
more indolent course of disease for patients with 
SDHA mutated WT GISTs [41].
SDH proficient ‘wT’ GiST
In the absence of the well-characterized frequent 
RTK mutations further, far less frequent muta-
tions have been described in the members of the 
downstream signaling pathway, with mutations 
in BRAF (V600E), HRAS, NRAS or PIK3CA 
genes. These mutations presumably cause the 
constitutive activation of KIT downstream sig-
nal pathways. In addition, KIT/PDGFRA WT 
GIST may be related to syndromic neurofi-
bromatosis type I (NF-1) disease, associated with 
NF1 protein loss of function due to genomic 
inactivation of the NF1 gene [5].
Hostein et al. screened 321 GISTs with 70 
WT GISTs for BRAF mutation. Similar to 
other tumor types where BRAF mutations are 
more commonly observed, the mutations seen 
in GIST are also located within the exon 15 
V600E hot spot. BRAF V600E was detected 
in nine (13%) of the 70 WT GISTs and no 
mutations were detected in GISTs bearing KIT 
or PDGFRA mutations. Interestingly BRAF 
V600E detection in the tumor did not result in 
a higher expression of the B-raf protein or the 
preferential activation of the p42/44 MAPK 
signaling pathway compared with GISTs with-
out the BRAF mutation [42]. KIT, PDGFRA and 
BRAF WT GISTs are commonly referred to as 
‘triple-negative’ GISTs.
Miettinen and colleagues noted that patients 
with NF1 are overrepresented by at least 
45-fold among GIST patients and GISTs occur 
in approximately 5–25% of NF1 patients. 
NF1-associated GISTs develop secondary to a 
somatic inactivation of the WT NF1 allele in 
the tumor and are commonly multicentric, pre-
dominantly located in the small intestine and 
lack KIT and PDGFRA mutations. The major-
ity of NF1-associated GISTs present as small, 
low mitotic index lesions and they are associ-
ated with quite favorable long-term clinical out-
comes reflected in low recurrence and metastases 
rates. Interestingly NF-1 associated GISTs aris-
ing from the duodenum display an aggressive 
behavior, being large mitotically active tumors 
with pronounced metastatic potential [43].
A small subgroup of KIT/PDGFRA WT 
GIST, referred as ‘quadruple WT GIST’ (Q-WT 
GIST), that lack mutations in any of the known 
KIT exons (8, 9, 11, 13, 14, 17) or PDGFRA 
exons (12, 14, 18) or RAS pathways, including 
BRAF (exons 11, 15) and RAS (exons 2, 3), or 
NF1, and yet retain an intact SDH complex 
(SDHB IHC positive, and no mutations in 
SDH) has been identified. The true clinical rele-
vance of this subgroup is yet to be elucidated [44].
Most recently two oncogenic RTK translo-
cations were reported in a subset of nongastric 
Q-WT GISTS [45,46]. Two cases with ETV6-
NTRK3 fusion (in a colonic and a rectal 
Q-WT GIST) and one with FGFR1-TACC1 
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translocation (in a small intestinal Q-WT GIST) 
were found. Both of these alterations have been 
identified in other malignancies and are known 
to constitutively activate the target kinases. These 
RTK translocations found in a subset of Q-WT 
GIST seem to define a novel biological class of 
GIST arising in nongastric sites. The oncogenic 
RTK fusion proteins could represent potential 
therapeutic targets. If confirmed in larger series, 
routine testing for RTK t ranslocation may be 
indicated for Q-WT GIST [45,46].
●● Genetically unstable GiST
The accumulation of chromosomal abnor-
malities correlates with the biological behavior 
of GISTs. About two-thirds of GISTs exhibit 
14 monosomy or partial loss of 14q, and half 
of them have loss of the long arm of chromo-
some 22. Chromosome 14 or 22 aberrations are 
linked to a borderline malignant potential. An 
aggressive biology is associated with the loss of 
chromosome 1p, 9p (spanning CDKN2A or 
p16INK4A) and 11p regions. Gain in chromo-
somal segments 8q and 17q have been associ-
ated with increased metastatic potential. It is an 
interesting observation that while an unstable 
karyotype correlates with the presence of GIST 
mutations, KIT/PDGFRA WT GISTs are 
genomically stable [47,48].
Combined prognostic value of mutational 
status in treatment-naive GiST
As detailed above individual genetic altera-
tions, for instance KIT exon 11 deletions, 
were reported already a decade ago as an inde-
pendent adverse prognostic factor in patients 
with untreated GIST [11]. However, until very 
recently, the combined prognostic value of the 
most relevant genetic GIST subtypes has not 
been elucidated. Rossi et al. analyzed a series 
of 451 untreated primary localized GISTs for 
KIT, PDGFRA and BRAF mutations [49] and 
found that mutational status is a significant 
prognostic indicator of overall survival (OS) 
in treatment-naive, localized GISTs. Patients 
with KIT-mutated tumors had a worse outcome 
than PDGFRA-mutated or ‘triple-negative’ 
(KIT, PDGFRA, BRAF WT) cases. Based on 
multivariable Cox regression models the authors 
identified three distinct molecular risk groups. 
Group I, consisting of PDGFRA exon 12, BRAF 
and KIT exon 13-mutated cases, exhibited the 
best clinical outcome. The intermediate risk 
(HR: 3.06) Group II, included ‘triple-negative’, 
KIT exon 17, PDGFRA exon 18 D842V and 
PDGFRA exon 14-mutated GISTs. Group 
III, comprised of KIT exon 9 and exon 11 
and PDGFRA non-D842V exon 18 mutant 
GISTs, displayed the worst clinical outcome 
(HR: 4.52). This study clearly highlighted the 
prognostic impact of mutational status on the 
natural history of GIST. Inclusion of molecular 
prognostic grouping into currently used clin-
icopathologic risk stratification criteria could 
clearly fine tune the decision-making process 
for adjuvant therapy.
●● Therapeutic implications of different 
genetic subtypes of GiST
Due to its ubiquitous role in the pathogenesis 
of GISTs, KIT has become a universal thera-
peutic target. Imatinib, a competitive inhibitor 
of the ATP-binding domain can only bind to 
the inactive conformation of KIT and its pro-
nounced clinical efficacy was confirmed one and 
a half decades ago [50,51]. Imatinib represents the 
standard upfront medication for the treatment 
of advanced/metastatic GIST, with an overall 
80% disease control rate (objective response or 
stable disease), a median progression-free sur-
vival (PFS) of approximately 20 months and a 
median OS of around 50 months [52,53].
Over the last decade KIT mutational status 
has emerged as a strong predictive indicator of 
treatment response. GISTs with KIT exon 11 
mutated genotype show a marked, approxi-
mately 70% objective response rate (ORR; 
complete response/partial response) as compared 
with the 40–45% ORR seen in exon 9 mutant 
and WT GISTs. The ORR advantage seen in 
exon 11 mutant patients translates into an addi-
tional OS gain of approximately 20 months for 
this subgroup compared with exon 9 mutated 
and ‘WT’ GISTs (60 vs 40 months for exon 9 
mutant and WT GIST, respectively) [52,53].
In the pooled analysis of the two pivotal 
Phase III trials comparing 400 versus 800 mg 
daily imatinib dose, the sole predictive factor of 
response was the presence of a KIT exon 9 muta-
tion. The estimated risk of progression or death 
was reduced by 42% in the high-dose arm (com-
pared with the standard-dose arm) in patients 
with KIT exon 9 mutated tumors. However, no 
significant difference in OS was seen between 
patients treated with 400 and 800 mg imatinib, 
irrespective of mutational status. The study con-
cluded that for most patients, the recommended 
daily dose is 400 mg daily, with the exception of 
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KIT exon 9 mutated tumors where the 800 mg 
dose can be considered [54].
Approximately, 5% of patients with GIST do 
not express KIT, but may have tumors that har-
bor imatinib-sensitive KIT or PDGFRA muta-
tions; therefore, patients with KIT-negative 
GISTs should not, a priori, be denied imatinib 
therapy and tumor samples should be sent for 
mutational analysis [55].
Despite majority of GIST patients benefit-
ing from imatinib treatment, approximately 
10–15% of them show primary resistance with 
early progression within 3–6 months of initi-
ating therapy, in keeping with primary resist-
ance. Although 80–85% patients with advanced 
GIST benefit from imatinib treatment, 40–50% 
of patients subsequently develop secondary 
resistance to the agent with a median time to 
progression of about 24 months [20,52,56].
●● Primary imatinib resistance
The accumulated results of preclinical and 
clinical research have provided powerful tools 
in the explanation, prediction and manage-
ment of primary resistance. Both primary and 
secondary resistance to imatinib can be par-
tially explained by a conformational shift in the 
kinase domain of KIT and PGFRA that favors 
the activated state [51]. Preclinical data indi-
cated that PDGFRA isoforms with a substitu-
tion involving codon D842 in exon 18 (D842V, 
RD841–842KI, DI842–843IM) lead to pri-
mary resistance to imatinib, with the exception 
of D842Y. Other mutations in exon 18 (D846Y, 
N848K, Y849K and HDSN845–848P) were 
found to be imatinib sensitive. Imatinib can only 
bind to the inactive conformation of both the 
KIT and PDGFRA receptors. PDGFRA D842V 
mutation results in a distortion of the kinase 
activation loop, thus strongly tilting the protein 
conformation in favor of the activated struc-
ture. In clinical trials PDGFRA mutant GISTs 
showed a mild sensitivity to drug (66%) except 
the exon 18 D842 V mutation which proved to 
be resistant [15,57]. However, a most recent large 
multicenter observational study reported objec-
tive response to imatinib in a small proportion of 
patients with PDGFRA D842V-mutated GIST. 
Out of 16 patients with the mutation 12.5% had 
partial response, 18.8% had stable disease and 
56.3% had PD as best response according to 
Choi criteria. Median time to progression was 
8.0 months (range: 0–42). The authors of the 
report rightly concluded that as patients with 
PDGFRA D842V-mutated GIST do have a 
small chance of responding to standard TKI 
treatment, imatinib should not be universally 
denied in patients harboring this mutation [58].
It is currently unclear how the predictive 
power of genetic alterations seen in the advanced 
setting may translate into decision-making 
regarding adjuvant therapy. The two adjuvant 
trials (the USA ACOSOG Z 9001 and the 
German–Scandinavian study) have failed to 
demonstrate that a specific mutation can predict 
a better RFS and OS in treated patients [16,59].
In the ACOSOG Z 9001 trial on multivari-
able analysis of patients tumor genotype was 
not significantly associated with RFS, how-
ever patients with KIT exon 11 deleted tumors 
assigned to 1 year of adjuvant imatinib did have 
a longer RFS. The excellent survival of patients 
with tumors harboring PDGFRA mutations in 
the placebo group provides a good argument that 
these patients may not require adjuvant treat-
ment [16]. In the German–Scandinavian study 
KIT exon 11 mutant GIST patients benefited 
from the longer 3-year treatment, whereas no 
significant improvement over 12 months of 
imatinib was found in KIT exon 9 or PDGFRA 
mutant or WT patients (note that the number of 
patients were small in these later categories) [59].
In a small series of seven metastatic NF1-
associated GIST patients, three of the four 
imatinib-treated patients showed primary resist-
ance to the treatment (all three tumors were 
‘WT’ GISTs). The fourth metastatic patient 
with an exon 18 mutated tumor had temporary 
stable disease. Median OS for this four-patient 
cohort was 21 months [60].
Rege and colleagues in their seven patient 
cohort of metastatic ‘pediatric-type’ SDH-
deficient adult GISTs reported absolute pri-
mary resistance to imatinib in all of the cases. 
In contrast to this, in a more recent 2015 report 
4/5 of imatinib-treated ‘pediatric-type’ SDHA-
mutant metastatic GISTs showed a longer than 
6-month PFS, with two ongoing responses at 19 
and 58 months [61]. This later observation begs 
the question whether SDHA mutational status 
shall be performed routinely in SDH-deficient 
tumors as assessed by IHC.
Alternate signaling pathway mutations (like 
BRAF exon 15 activating mutation) in patients 
lacking identifiable PDGFRA or KIT muta-
tions can be potential alternative mechanisms 
explaining their frequent primary resistance to 
imatinib [62–64].
10.2217/fon-2016-0192
review Szucs, Thway, Fisher et al.
future science group
●● Secondary imatinib resistance
Acquisition of KIT or PDGFRA secondary muta-
tions represent the most frequent mechanism of 
imatinib resistance in GIST [64,65]. Radiological 
evidence of clonal resistance can be detected as 
the appearance of one or more areas of increased 
vascularity within a previously responding or 
stable lesion. These lesions can precede by several 
months PD) according to Response Evaluation 
Criteria In Solid Tumors (RECIST). In a study 
of TKI pretreated patients [66], the mutational 
status of individual nodules within a dominant 
tumor mass confirmed intra- and inter-lesional 
mutational heterogeneity between co-existing 
nodules. In total, 83% of samples had at least 
one secondary mutation, 67% had two to five 
different secondary mutations in different 
tumor samples and 34% had more than two 
mutations in the same clone. Secondary muta-
tions clustered in the KIT ATP-binding pocket 
(exon 13) and kinase activation loop (exon 17). 
KIT amplification was detected by FISH in two 
of the ten metastases lacking secondary KIT 
mutations. No KIT kinase resistance mutations 
were detected in KIT/PDGFRA WT GISTs or 
in KIT-mutant GISTs showing unusual mor-
phology and/or loss of KIT expression by IHC. 
These results clearly expose the emergence of 
heterogeneous resistance mechanisms in these 
tumors. Furthermore, these data indicate that 
repeat biopsy (with mutational analysis) may not 
be relevant in metastatic GIST and highlight 
the therapeutic challenges involved in manag-
ing heavily pretreated patients [66]. Emergence 
of polyclonal imatinib resistance poses a great 
difficulty in developing effective single agent 
next-generation kinase inhibitors.
Secondary KIT exon 17 mutations affecting 
the activation loop stabilize the active receptor 
conformation, while imatinib can only bind and 
inhibit the nonactivated (auto-inhibited) con-
formation of KIT. Activation loop mutations 
therefore indirectly induce imatinib resistance 
by shifting the equilibrium strongly in favor of 
the active conformation [21].
In a Phase I/II trial half of the patients pro-
gressing on imatinib had a secondary KIT muta-
tion [67]. Mutational distribution was nonran-
dom, secondary mutations clustering in exons 
13 and 14, encoding the drug/ATP-binding 
pocket of the receptor and in exon 17, encoding 
the kinase activation loop. The most commonly 
detected secondary mutation was the exon 13 
V654A. Two tumors had secondary mutations in 
KIT exon 18. One patient had distinct second-
ary mutations in separate lesions, that of exon 
13 V654A and exon 17 D816H respectively. Of 
the four primary PDGFRA mutant samples one 
had a secondary mutation in exon 18 (primary 
mutation in exon 12), two lacked secondary 
mutations (both had primary exon 18 D842V 
mutations) and in the fourth case there was 
no postimatinib sample available. More inter-
estingly, in the post-imatinib samples of eight 
KIT or PDGFRA wild type GISTs no second-
ary mutations were found. Secondary mutations 
were more likely to be found in patients who 
initially harbored KIT exon 11 mutations (73%) 
as compared with KIT exon 9 mutations (19%). 
The higher rate of secondary mutations in the 
primary exon 11 mutant subgroup, is likely to 
be due to the longer exposure to imatinib. In 
preclinical in vitro studies sunitinib potently 
inhibited the kinase activity of KIT receptors 
that contained imatinib-resistant secondary 
mutations in the drug/ATP-binding pocket, 
such as V654A (exon 13) and T670I (exon 14). 
Furthermore, in vitro sunitinib was relatively 
ineffective at inhibiting KIT receptors with sec-
ondary mutations affecting the activation loop. 
In keeping with these findings, clinical trial data 
have shown that PFS and OS were longer and 
the clinical benefit rate was higher for patients 
with tumors harboring the KIT exon 13 or 14 
ATP-binding-pocket mutations than those with 
KIT exon 17 or 18 activation loop mutations [67].
Amplification of the KIT and/or PDGFRA 
genes has also been postulated as a potential 
mechanism for either primary or delayed TKI 
resistance [67,68]. Some GISTs lacking second-
ary kinase mutations do show genomic ampli-
fication of KIT and/or become hemi- and/or 
homo-zygous for the primary KIT mutation 
 undergoing deletion of the WT KIT allele [68].
IGF1R amplification may represent another 
mechanism of de novo or acquired imatinib 
resistance. It has to be noted that IGF1R over-
expression was detected in the overwhelm-
ing majority (89%) of SDH-negative gastric 
GISTs but in only 1% of SDHB-positive gastric 
GISTs [69].
●● Treatment beyond imatinib
Sunitinib and regorafenib have been approved 
for imatinib-resistant GIST based on placebo 
controlled randomized Phase III trials [70,71].
The response to second-line sunitinib cor-
relates with the primary (pre-imatinib) tumor 
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mutation status [67,72]. In a worldwide, open-
label treatment-use study of 1124 patients resist-
ant or intolerant to imatinib a median PFS of 
7.1 months was reported on sunitinib. The PFS 
in patients with a primary KIT exon 9 mutation 
was significantly better as compared with those 
with primary exon 11 mutation, with figures of 
12.3 and 7.0 months, respectively. Moreover, pri-
mary KIT exon 9 mutation was associated with 
a longer OS and higher ORR as compared with 
exon 11 GISTs [72].
As far as secondary KIT mutations are con-
cerned, for primarily KIT mutant GIST patients 
the median PFS and OS with sunitinib was sig-
nificantly longer for secondary KIT exon 13 
or 14 mutations than for those with secondary 
exon 17 or 18 mutations [67]. These results cor-
roborate the in vitro findings which showed that 
sunitinib effectively inhibits the phosphorylation 
of KIT double mutants where secondary muta-
tion affected the drug/ATP-binding pocket. On 
the other hand, sunitinib has very little activity 
against KIT double mutants where secondary 
mutations affected the activation loop [73].
Moreover, preclinical studies of imatinib-
resistant GIST cell lines evaluating sunitinib 
sensitivity showed that only KIT T670I (gate-
keeper) and V654A mutants were sensitive to 
sunitinib, while PDGFRA D842V (activa-
tion loop) mutants remained resistant [73]. 
Unfortunately, the available clinical data are yet 
too limited to investigate the effects of PDGFRA 
mutations on eff icacy outcomes  following 
 sunitinib treatment [67,72].
There is little evidence available in regard 
of the predictive power of mutational status in 
the third-line regorafenib treatment of GISTs; 
however, regorafenib showed efficacy in all 
genetic subtypes of GISTs including exon 9 and 
PDGFRA D842V mutants [71,74].
Conclusion
The discovery of activating mutations in KIT 
and PDGFRA and their role in the pathogenesis 
of GIST has revolutionized our understanding 
of the biology and therapy of this disease. The 
introduction of imatinib has ultimately led to 
a radical improvement in life expectancy of 
advanced GIST patients. However, it is clear 
that GISTs are composed of many different 
molecular subtypes, with differing clinical char-
acteristics and response to therapy. The detec-
tion of specific somatic genetic changes in GISTs 
can provide potential predictive and prognostic 
information for guiding therapy. We can con-
clude that the term ‘WT’ GIST is outdated by 
a series of recent findings, and in case it is used 
reference always should be made which genes 
it applies to (i.e., KIT/PDGFRA WT GIST or 
KIT/PDGFRA/BRAF WT GIST and so on).
Nonhot spot exon 8 and exon 14 mutations of 
the KIT receptor are extremely rare and are not 
routinely screened for. There is a genuine con-
cern that without identifying these rare muta-
tions we miss to identify vital information about 
the biological behavior and treatment sensitiv-
ity (both in the adjuvant and metastatic setting) 
of these genetic subtypes. KIT exon 11 mutant 
patients are twice as likely to respond to imatinib 
than those with exon 9 mutant or WT GISTs. 
Moreover, higher response rates to imatinib in 
the KIT exon 11 mutant group translates into 
a PFS and OS advantage as compared with all 
non-KIT exon 11 mutant GISTs. The presence 
of a KIT del-inc557/558 mutation in a study 
of patients from the pre-imatinib era, reported 
that this mutation was strongly associated with 
poorer outcomes both in high-risk and non-
high-risk gastric GIST, indicating its additional 
prognostic value for patient selection for adju-
vant therapy. It remains to be shown whether 
patients with GISTs with KIT del-inc557/558 
genotype should not be kept longer (or even life-
long) on standard adjuvant imatinib treatment 
(i.e., 3 years).
KIT exon 9 mutations have been associated 
with a poor clinical prognosis as compared with 
other mutations. However, the worse prognosis 
of KIT exon 9 mutants seems to be related to 
the almost exclusive high-risk extra-gastric tumor 
location of these GISTs rather than to an intrinsic 
aggressive biologic behavior. KIT exon 9 mutant 
GISTs are more likely to respond to the higher 
800 mg dose of imatinib, and in the advanced 
setting patients there is a strong recommenda-
tion of starting patients with tumors harbor-
ing theses mutations on the higher dose. The 
optimal dose of imatinib in the adjuvant setting 
for KIT exon 9 mutant GISTs is yet to be eluci-
dated. Identification of PDGFRA mutations in 
GIST proved to be a strong predictor of good 
clinical outcome and this molecular factor could 
therefore add a significant value to the current 
consensus risk criteria used for GIST stratifi-
cation. In addition, given that these mutations 
comprise the majority of cases with the imatinib-
resistant p.D842V subtype, mutational testing is 
highly relevant in order to avoid overtreatment 
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of gastric tumors with imatinib in the adjuvant 
setting. As tumors with certain mutations such 
as PDGFRA D842V mostly have primary resist-
ance to imatinib and sunitinib, patients should 
be offered participation in clinical trials of novel 
agents. A recent large multicenter observational 
study has suggested that some tumors with the 
D842V mutation may respond to standard 
tyrosine kinase therapy. While tumors with no 
PDGFRA or KIT mutations (WT GISTs) are 
generally considered to be less responsive to these 
agents, more focus should be directed at the exact 
mutational landscape of these cancers with regard 
to the therapeutic decision-making process. 
These are important observations that should be 
factored into the decision-making process prior 
to commencing tyrosine kinase therapy.
Future perspective
Inevitably all currently available standard 
treatment options lose their efficacy to con-
trol advanced GIST. Ongoing preclinical and 
clinical research is focusing on evaluating novel 
therapeutic approaches to overcome primary 
and secondary resistance to imatinib and the 
other two currently available licensed medi-
cations, sunitinib and regorafenib. Targeting 
deregulated downstream pathways shall pro-
vide further treatment options in the man-
agement of imatinib/sunitinib/regorafenib 
insensitive/resistant GISTs.
Emerging information about the prognos-
tic value of different, specific mutations war-
rants further evaluation, possibly using pooled 
cohorts stratified for the mutational status from 
the available prospective clinical trials in the 
a djuvant setting.
Currently, adjuvant therapy in ‘high-risk’ 
WT GIST and the optimal systemic treatment 
for metastatic WT GIST remain debatable ‘hot 
topic’ questions, with no clear-cut guidelines. 
The group of WT patients is heterogeneous 
and further attempts should be made to further 
delineate individual molecular subtypes, in order 
to guide future clinical trial development and 
optimize systemic therapy.
executive summary
Classification of gastrointestinal stromal tumors
 ●  Gastrointestinal stromal tumors (GISTs) are the most common type of mesenchymal tumors of the digestive tract, 
mainly defined by the presence or lack of mutually exclusive gain-of-function mutations in the KIT and PDGFRA 
receptors.
 ●  GISTs historically referred to as ‘wild-type’ (WT) GISTs are a very heterogeneous group which do not have a detectable 
mutation in either the KIT or the PDGFRA receptor genes, while KIT activation by phosphorylation is still detectable in 
these tumors.
 ●  WT GISTs can be split into two large groups, based on whether they are proficient or deficient in the succinate 
dehydrogenase complex.
 ●  Detecting mutations in alternative pathways can further subclassify WT GISTs.
Therapeutic implications of genetic subtypes
 ●  KIT exon 11 mutant patients are twice as likely to respond to imatinib than those with exon 9 mutant or WT GISTs with 
a progression-free and overall survival advantage as compared with all non-KIT exon 11 mutant GISTs.
 ●  KIT exon 9 mutant GISTs are more likely to respond to the higher 800 mg dose of imatinib, and in the advanced setting 
patients can be started ab ovo on the higher dose.
 ●  The PDGFRA D842V isoform with a substitution involving codon D842 in exon 18 is generally believed to lead to 
primary imatinib resistance. Caution should be exercised when it comes to therapeutic decisions as recent data 
suggest some response to imatinib in this subset of tumors.
 ●  While SDH-deficient ‘pediatric-type’ GISTs have been previously attributed absolute primary imatinib resistance, most 
recent reports suggest imatinib responsiveness in SDHA-mutated tumors.
 ●  Acquisition of secondary mutations in either KIT or PDGFRA represents the most frequent mechanism of imatinib 
resistance in GIST.
 ●  Adjuvant therapy in ‘high-risk’ WT GIST and the optimal systemic treatment for metastatic WT GIST remain debatable 
‘hot topic’ questions, with no clear-cut clinical guidelines.
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